摘要
Mesenchymal stem cells(MSCs) are plastic-adherent cells with a characteristic surface phenotype and properties of self-renewal, differentiation, and high proliferative potential. The characteristics of MSCs and their tumortropic capability make them an ideal tool for use in cell-based therapies for cancer, including glioma. These cells can function either through a bystander effect or as a delivery system for genes and drugs. MSCs have been demonstrated to inhibit the growth of glioma and to improve survival following transplantation into the brain. We briefly review the current data regarding the use of MSCs in the treatment of glioma and discuss the potential strategies for development of a more specific and effective therapy.
胶质瘤是颅内发病率最高的恶性肿瘤,虽然临床上可以用"手术+化疗"的方法进行治疗,但由于其浸润性,对化疗药物的低敏感性等原因,常在治疗后复发,严重威胁人类生命健康。间充质干细胞(MSC)是干细胞中的一员,具有增殖能力强、分化潜能大、免疫原性低及采集方便等优点,其趋化性更使MSC成为肿瘤治疗的一个理想工具。本文对干细胞治疗胶质瘤的研究现状进行了归纳总结,着重阐述了MSC的旁分泌途径作用及作为基因载体导入肿瘤坏死因子相关凋亡诱导配体(TRAIL)、溶瘤病毒等其他治疗基因的生物功能,以期对进一步的治疗研究提供帮助。
基金
supported by the National High-Tech R&D Program(863)of China(No.2015AA020306)